DE60203481T2 - Piperidinderivate als neurokinin 1 antagonisten - Google Patents
Piperidinderivate als neurokinin 1 antagonisten Download PDFInfo
- Publication number
- DE60203481T2 DE60203481T2 DE60203481T DE60203481T DE60203481T2 DE 60203481 T2 DE60203481 T2 DE 60203481T2 DE 60203481 T DE60203481 T DE 60203481T DE 60203481 T DE60203481 T DE 60203481T DE 60203481 T2 DE60203481 T2 DE 60203481T2
- Authority
- DE
- Germany
- Prior art keywords
- phenyl
- bis
- piperidin
- trifluoromethyl
- methanone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title description 5
- 239000005557 antagonist Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 219
- -1 4-methyl-piperazinyl Chemical group 0.000 claims description 149
- 238000000034 method Methods 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000002757 morpholinyl group Chemical group 0.000 claims description 21
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 239000011737 fluorine Substances 0.000 claims description 13
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000460 chlorine Substances 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 125000004193 piperazinyl group Chemical group 0.000 claims description 12
- PFNJHPGSNGDBSO-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-piperazin-1-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCNCC1)C1=CC=CC=C1)(F)F PFNJHPGSNGDBSO-SFTDATJTSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 7
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 claims description 6
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- UDRBQEGZZSNZJV-PKTZIBPZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(3-bromophenyl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=CC=C1)Br)C1=CC=CC=C1)(F)F UDRBQEGZZSNZJV-PKTZIBPZSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 229940044551 receptor antagonist Drugs 0.000 claims description 6
- 239000002464 receptor antagonist Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 6
- GJMIULBZYICSMI-SFTDATJTSA-N 1-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-(4-chlorophenyl)piperidin-4-yl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C(C(F)(F)F)=O)C2=CC=C(C=C2)Cl)C=C(C1)C(F)(F)F)(F)F GJMIULBZYICSMI-SFTDATJTSA-N 0.000 claims description 5
- GJMIULBZYICSMI-UHFFFAOYSA-N 1-[4-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(4-chlorophenyl)piperidin-4-yl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound C1CN(C(=O)C(F)(F)F)CCN1C1C(C=2C=CC(Cl)=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 GJMIULBZYICSMI-UHFFFAOYSA-N 0.000 claims description 5
- PFQVGWLVKBANFL-SFTDATJTSA-N FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CC(CC2)=O)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CC(CC2)=O)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F PFQVGWLVKBANFL-SFTDATJTSA-N 0.000 claims description 5
- BRJRXLQWTMSQBS-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-thiomorpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCSCC1)C1=CC=CC=C1)(F)F BRJRXLQWTMSQBS-SFTDATJTSA-N 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- UQABNGOOEFUUOI-ZEQRLZLVSA-N [4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-cyclopropylmethanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C(=O)C1CC1)C1=CC=CC=C1)(F)F UQABNGOOEFUUOI-ZEQRLZLVSA-N 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000001590 oxidative effect Effects 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- VURZIUHIBJZQJU-ZEQRLZLVSA-N 2-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-N,N-dimethylacetamide Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)CC(=O)N(C)C)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F VURZIUHIBJZQJU-ZEQRLZLVSA-N 0.000 claims description 3
- FMVSQTXHPKIBOG-NSOVKSMOSA-N FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)CC(=O)NC2=CC=C(C=C2)F)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)CC(=O)NC2=CC=C(C=C2)F)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F FMVSQTXHPKIBOG-NSOVKSMOSA-N 0.000 claims description 3
- RSCZASMERGDWQG-NSOVKSMOSA-N [(3R,4S)-4-(4-benzylpiperazin-1-yl)-3-phenylpiperidin-1-yl]-[3,5-bis(trifluoromethyl)phenyl]methanone Chemical compound C(C1=CC=CC=C1)N1CCN(CC1)[C@@H]1[C@@H](CN(CC1)C(=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=CC=C1 RSCZASMERGDWQG-NSOVKSMOSA-N 0.000 claims description 3
- CCXDRJAINCWDAQ-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-chlorophenyl)-4-morpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=CC=C(C=C1)Cl)(F)F CCXDRJAINCWDAQ-SFTDATJTSA-N 0.000 claims description 3
- QDZJLISLPHCAPG-PKTZIBPZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-chlorophenyl)-4-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=CC=C1)C1=CC=C(C=C1)Cl)(F)F QDZJLISLPHCAPG-PKTZIBPZSA-N 0.000 claims description 3
- NTDHCKSZBFQTJJ-VXKWHMMOSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-fluorophenyl)-4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C)C1=CC=C(C=C1)F)(F)F NTDHCKSZBFQTJJ-VXKWHMMOSA-N 0.000 claims description 3
- OJCHNZGIVNTAKX-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-fluorophenyl)-4-morpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=CC=C(C=C1)F)(F)F OJCHNZGIVNTAKX-SFTDATJTSA-N 0.000 claims description 3
- PSRRKURJBFCJJI-ZEQRLZLVSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-(4-pyrazin-2-ylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C=2N=CC=NC=2)C=2C=CC=CC=2)=C1 PSRRKURJBFCJJI-ZEQRLZLVSA-N 0.000 claims description 3
- QOPIJTBAENVABP-ZEQRLZLVSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(4-cyclopropylpiperazin-1-yl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C1CC1)C1=CC=CC=C1)(F)F QOPIJTBAENVABP-ZEQRLZLVSA-N 0.000 claims description 3
- SVAYRKLDOZPACO-VXKWHMMOSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(4-methylpiperazin-1-yl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C)C1=CC=CC=C1)(F)F SVAYRKLDOZPACO-VXKWHMMOSA-N 0.000 claims description 3
- VWNSKHONTPQIBQ-SXOMAYOGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(4-morpholin-4-ylphenyl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=C(C=C1)N1CCOCC1)C1=CC=CC=C1)(F)F VWNSKHONTPQIBQ-SXOMAYOGSA-N 0.000 claims description 3
- VXKCYYXJWDLBCZ-FTJBHMTQSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[4-(2-methoxyethylamino)phenyl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=C(C=C1)NCCOC)C1=CC=CC=C1)(F)F VXKCYYXJWDLBCZ-FTJBHMTQSA-N 0.000 claims description 3
- JYFFYYUGBWGEKI-IZLXSDGUSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[4-(4-methylpiperazin-1-yl)phenyl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=C(C=C1)N1CCN(CC1)C)C1=CC=CC=C1)(F)F JYFFYYUGBWGEKI-IZLXSDGUSA-N 0.000 claims description 3
- RFBURTLUSXOIHK-DQEYMECFSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[4-(cyclopropylmethyl)piperazin-1-yl]-3-(4-fluorophenyl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)CC1CC1)C1=CC=C(C=C1)F)(F)F RFBURTLUSXOIHK-DQEYMECFSA-N 0.000 claims description 3
- HDGHBMSKSIBEPD-DQEYMECFSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[4-(cyclopropylmethyl)piperazin-1-yl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)CC1CC1)C1=CC=CC=C1)(F)F HDGHBMSKSIBEPD-DQEYMECFSA-N 0.000 claims description 3
- IXPJTNGFNRDHMI-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-morpholin-4-yl-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=CC=CC=C1)(F)F IXPJTNGFNRDHMI-SFTDATJTSA-N 0.000 claims description 3
- XRUKHJOJTLIFMF-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-chlorophenyl)-4-[4-(cyclopropylmethyl)piperazin-1-yl]piperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCN(CC3CC3)CC2)C=2C=CC(Cl)=CC=2)=C1 XRUKHJOJTLIFMF-UHFFFAOYSA-N 0.000 claims description 3
- MMWYCGIIXQMACZ-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-chlorophenyl)-4-pyrrolidin-1-ylpiperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCCC2)C=2C=CC(Cl)=CC=2)=C1 MMWYCGIIXQMACZ-UHFFFAOYSA-N 0.000 claims description 3
- IMBFYCYNNWNYJR-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-methylphenyl)-4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound C1CN(C)CCN1C1C(C=2C=CC(C)=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 IMBFYCYNNWNYJR-UHFFFAOYSA-N 0.000 claims description 3
- SKVLOVMYMAQCLU-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[4-(4-cyclopropylpiperazin-1-yl)-3-(4-methylphenyl)piperidin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1C1C(N2CCN(CC2)C2CC2)CCN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 SKVLOVMYMAQCLU-UHFFFAOYSA-N 0.000 claims description 3
- QOPIJTBAENVABP-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[4-(4-cyclopropylpiperazin-1-yl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCN(CC2)C2CC2)C=2C=CC=CC=2)=C1 QOPIJTBAENVABP-UHFFFAOYSA-N 0.000 claims description 3
- HDGHBMSKSIBEPD-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[4-[4-(cyclopropylmethyl)piperazin-1-yl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCN(CC3CC3)CC2)C=2C=CC=CC=2)=C1 HDGHBMSKSIBEPD-UHFFFAOYSA-N 0.000 claims description 3
- IKDCKWKTTNIJRM-UHFFFAOYSA-N [4-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(4-methylphenyl)piperidin-4-yl]piperazin-1-yl]-cyclopropylmethanone Chemical compound C1=CC(C)=CC=C1C1C(N2CCN(CC2)C(=O)C2CC2)CCN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 IKDCKWKTTNIJRM-UHFFFAOYSA-N 0.000 claims description 3
- UQABNGOOEFUUOI-UHFFFAOYSA-N [4-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-cyclopropylmethanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCN(CC2)C(=O)C2CC2)C=2C=CC=CC=2)=C1 UQABNGOOEFUUOI-UHFFFAOYSA-N 0.000 claims description 3
- 230000002152 alkylating effect Effects 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims description 2
- CGARRQSZKTWYFN-NSOVKSMOSA-N 1-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-2-phenylethanone Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C(CC2=CC=CC=C2)=O)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F CGARRQSZKTWYFN-NSOVKSMOSA-N 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- MPHLYYLVNQTJED-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-fluorophenyl)-4-piperazin-1-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCNCC1)C1=CC=C(C=C1)F)(F)F MPHLYYLVNQTJED-SFTDATJTSA-N 0.000 claims description 2
- JEIFPGIGTTZXDQ-DQEYMECFSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[4-(morpholine-4-carbonyl)piperazin-1-yl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C(=O)N2CCOCC2)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F JEIFPGIGTTZXDQ-DQEYMECFSA-N 0.000 claims description 2
- NTDHCKSZBFQTJJ-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-fluorophenyl)-4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound C1CN(C)CCN1C1C(C=2C=CC(F)=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 NTDHCKSZBFQTJJ-UHFFFAOYSA-N 0.000 claims description 2
- VWNHFOMGPDXVQE-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-methylphenyl)-4-[4-(morpholine-4-carbonyl)piperazin-1-yl]piperidin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1C1C(N2CCN(CC2)C(=O)N2CCOCC2)CCN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 VWNHFOMGPDXVQE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 197
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 125
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 120
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 59
- 239000011541 reaction mixture Substances 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- 238000007429 general method Methods 0.000 description 44
- 239000000203 mixture Substances 0.000 description 42
- 239000012074 organic phase Substances 0.000 description 40
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 36
- WAKMMQSMEDJRRI-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC(C(Cl)=O)=CC(C(F)(F)F)=C1 WAKMMQSMEDJRRI-UHFFFAOYSA-N 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 32
- 239000000741 silica gel Substances 0.000 description 32
- 229910002027 silica gel Inorganic materials 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 29
- 235000019341 magnesium sulphate Nutrition 0.000 description 29
- 238000003818 flash chromatography Methods 0.000 description 25
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 16
- 102100024304 Protachykinin-1 Human genes 0.000 description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000006260 foam Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 11
- 0 **C(C(C1)C(*)CCN1C(c1cc(*)cc(*)c1)=O)=CC=CC=* Chemical compound **C(C(C1)C(*)CCN1C(c1cc(*)cc(*)c1)=O)=CC=CC=* 0.000 description 10
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 10
- VDRJIVUPMPNZBO-UHFFFAOYSA-N 1-benzyl-3-phenylpiperidin-4-one Chemical compound C1C(C=2C=CC=CC=2)C(=O)CCN1CC1=CC=CC=C1 VDRJIVUPMPNZBO-UHFFFAOYSA-N 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 9
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical compound C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- XOFTVOBTWBJXCV-UHFFFAOYSA-N 1-[4-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(4-methylphenyl)piperidin-4-yl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound C1=CC(C)=CC=C1C1C(N2CCN(CC2)C(=O)C(F)(F)F)CCN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 XOFTVOBTWBJXCV-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 8
- 239000000829 suppository Substances 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 7
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
- 239000012425 OXONE® Substances 0.000 description 7
- 101800003906 Substance P Proteins 0.000 description 7
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 6
- NOTGAYRGZXJJAY-UHFFFAOYSA-N 1-benzyl-3-(4-fluorophenyl)piperidin-4-one Chemical compound C1=CC(F)=CC=C1C1C(=O)CCN(CC=2C=CC=CC=2)C1 NOTGAYRGZXJJAY-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- 229940087646 methanolamine Drugs 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- BKOCZVKJINCOGP-UHFFFAOYSA-N 1-benzyl-3-(4-chlorophenyl)piperidin-4-one Chemical compound C1=CC(Cl)=CC=C1C1C(=O)CCN(CC=2C=CC=CC=2)C1 BKOCZVKJINCOGP-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 5
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- FNAHDYMMDBHGFH-PKTZIBPZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(4-chlorophenyl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=C(C=C1)Cl)C1=CC=CC=C1)(F)F FNAHDYMMDBHGFH-PKTZIBPZSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- BZMMRNKDONDVIB-UHFFFAOYSA-N (1-ethoxycyclopropyl)oxy-trimethylsilane Chemical compound CCOC1(O[Si](C)(C)C)CC1 BZMMRNKDONDVIB-UHFFFAOYSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
- RASWPQQWDCBOBT-SFTDATJTSA-N 1-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C(C(F)(F)F)=O)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F RASWPQQWDCBOBT-SFTDATJTSA-N 0.000 description 3
- PQHKDSRNOXTBEK-UHFFFAOYSA-N 1-benzyl-3-(4-methylphenyl)piperidin-4-one Chemical compound C1=CC(C)=CC=C1C1C(=O)CCN(CC=2C=CC=CC=2)C1 PQHKDSRNOXTBEK-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- IUEYFYBTXUTFPR-SFTDATJTSA-N FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C(C(F)(F)F)=O)C2=CC=C(C=C2)F)C=C(C1)C(F)(F)F)(F)F Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C(C(F)(F)F)=O)C2=CC=C(C=C2)F)C=C(C1)C(F)(F)F)(F)F IUEYFYBTXUTFPR-SFTDATJTSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 102000003141 Tachykinin Human genes 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 125000001207 fluorophenyl group Chemical group 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 108060008037 tachykinin Proteins 0.000 description 3
- 239000002462 tachykinin receptor antagonist Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- FEMCLPXUDCOZID-VXKWHMMOSA-N (3,5-dichlorophenyl)-[(3R,4S)-4-(4-methylpiperazin-1-yl)-3-phenylpiperidin-1-yl]methanone Chemical compound ClC=1C=C(C=C(C1)Cl)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C)C1=CC=CC=C1 FEMCLPXUDCOZID-VXKWHMMOSA-N 0.000 description 2
- GITFHAZVNSAGFQ-VNYZMKMESA-N (3R,4S)-3-(2-chlorophenyl)-4-phenylpiperidine hydrochloride Chemical compound Cl.ClC1=CC=CC=C1[C@H]1[C@@H](C=2C=CC=CC=2)CCNC1 GITFHAZVNSAGFQ-VNYZMKMESA-N 0.000 description 2
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 2
- QJNGCOKNTAKKRL-VXKWHMMOSA-N 1-[(3R,4S)-1-benzyl-3-(4-chlorophenyl)piperidin-4-yl]piperazine Chemical compound C(C1=CC=CC=C1)N1C[C@H]([C@H](CC1)N1CCNCC1)C1=CC=C(C=C1)Cl QJNGCOKNTAKKRL-VXKWHMMOSA-N 0.000 description 2
- FZOYXRKWHSALEN-VXKWHMMOSA-N 1-[(3R,4S)-1-benzyl-3-phenylpiperidin-4-yl]piperazine Chemical compound C(C1=CC=CC=C1)N1C[C@H]([C@H](CC1)N1CCNCC1)C1=CC=CC=C1 FZOYXRKWHSALEN-VXKWHMMOSA-N 0.000 description 2
- OHKAQDSLJSMJNF-VXKWHMMOSA-N 1-[4-[(3R,4S)-1-benzyl-3-phenylpiperidin-4-yl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound C(C1=CC=CC=C1)N1C[C@H]([C@H](CC1)N1CCN(CC1)C(C(F)(F)F)=O)C1=CC=CC=C1 OHKAQDSLJSMJNF-VXKWHMMOSA-N 0.000 description 2
- RBNVUBWKLRJUEW-UHFFFAOYSA-N 1-benzyl-3-(2-chlorophenyl)piperidin-4-one Chemical compound ClC1=CC=CC=C1C1C(=O)CCN(CC=2C=CC=CC=2)C1 RBNVUBWKLRJUEW-UHFFFAOYSA-N 0.000 description 2
- OFRNQSIBXSEHOH-UHFFFAOYSA-N 1-benzyl-3-(2-methylphenyl)piperidin-4-one Chemical compound CC1=CC=CC=C1C1C(=O)CCN(CC=2C=CC=CC=2)C1 OFRNQSIBXSEHOH-UHFFFAOYSA-N 0.000 description 2
- HJWQJWIWGFPFRM-UHFFFAOYSA-N 1-benzyl-3-(3,4-dichlorophenyl)piperidin-4-one Chemical compound C1=C(Cl)C(Cl)=CC=C1C1C(=O)CCN(CC=2C=CC=CC=2)C1 HJWQJWIWGFPFRM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- XILVWQMCIFIHBH-VMPREFPWSA-N 2-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)CC(=O)NC2=C(C=CC=C2C)C)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F XILVWQMCIFIHBH-VMPREFPWSA-N 0.000 description 2
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FKIPQQZMEQKVAA-VXKWHMMOSA-N 4-[(3R,4S)-1-benzyl-3-(4-chlorophenyl)piperidin-4-yl]morpholine Chemical compound C(C1=CC=CC=C1)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=CC=C(C=C1)Cl FKIPQQZMEQKVAA-VXKWHMMOSA-N 0.000 description 2
- NUWWJEDKVHUTGY-VXKWHMMOSA-N 4-[(3R,4S)-1-benzyl-3-phenylpiperidin-4-yl]morpholine Chemical compound C(C1=CC=CC=C1)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=CC=CC=C1 NUWWJEDKVHUTGY-VXKWHMMOSA-N 0.000 description 2
- XFCPGAHDBKKEEC-UHFFFAOYSA-N 4-[3,5-bis(trifluoromethyl)phenyl]-4-[4-(cyclopropylmethyl)piperazin-1-yl]-3-(4-methylphenyl)piperidine-1-carbaldehyde Chemical compound C1=CC(C)=CC=C1C1C(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)(N2CCN(CC3CC3)CC2)CCN(C=O)C1 XFCPGAHDBKKEEC-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000007124 Tachykinin Receptors Human genes 0.000 description 2
- 108010072901 Tachykinin Receptors Proteins 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- MMWYCGIIXQMACZ-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-chlorophenyl)-4-pyrrolidin-1-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCCC1)C1=CC=C(C=C1)Cl)(F)F MMWYCGIIXQMACZ-SFTDATJTSA-N 0.000 description 2
- KLRSPDPICZTGQQ-IRLDBZIGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(2-chlorophenyl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=C(C=CC=C1)Cl)C1=CC=CC=C1)(F)F KLRSPDPICZTGQQ-IRLDBZIGSA-N 0.000 description 2
- KWXMVYLIGTVLST-UHFFFAOYSA-N [4-(3-aminopyrrolidin-1-yl)-3-(4-fluorophenyl)piperidin-1-yl]-[3,5-bis(trifluoromethyl)phenyl]methanone Chemical compound C1C(N)CCN1C1C(C=2C=CC(F)=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 KWXMVYLIGTVLST-UHFFFAOYSA-N 0.000 description 2
- WUTXDEVEGVQGBF-ZEQRLZLVSA-N [4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-(4-fluorophenyl)piperidin-4-yl]piperazin-1-yl]-cyclopropylmethanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C(=O)C1CC1)C1=CC=C(C=C1)F)(F)F WUTXDEVEGVQGBF-ZEQRLZLVSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001347 alkyl bromides Chemical class 0.000 description 2
- 150000001348 alkyl chlorides Chemical class 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006264 debenzylation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- GBDKKPDLEMYCMB-UHFFFAOYSA-N tert-butyl 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1C(C=2C=CC=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 GBDKKPDLEMYCMB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- FEMCLPXUDCOZID-UHFFFAOYSA-N (3,5-dichlorophenyl)-[4-(4-methylpiperazin-1-yl)-3-phenylpiperidin-1-yl]methanone Chemical compound C1CN(C)CCN1C1C(C=2C=CC=CC=2)CN(C(=O)C=2C=C(Cl)C=C(Cl)C=2)CC1 FEMCLPXUDCOZID-UHFFFAOYSA-N 0.000 description 1
- PGHZXZLMWSGLLW-SJORKVTESA-N (3R,4S)-3,4-diphenylpiperidine Chemical compound C1([C@H]2[C@H](CCNC2)C=2C=CC=CC=2)=CC=CC=C1 PGHZXZLMWSGLLW-SJORKVTESA-N 0.000 description 1
- AKQSNEVSNTWSAI-PPPUBMIESA-N (3R,4S)-3-(3-chlorophenyl)-4-phenylpiperidine hydrochloride Chemical compound Cl.ClC1=CC=CC([C@H]2[C@H](CCNC2)C=2C=CC=CC=2)=C1 AKQSNEVSNTWSAI-PPPUBMIESA-N 0.000 description 1
- DHWFDYLOWPZTDS-PPPUBMIESA-N (3R,4S)-3-phenyl-4-[3-(trifluoromethyl)phenyl]piperidine hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC([C@@H]2[C@@H](CNCC2)C=2C=CC=CC=2)=C1 DHWFDYLOWPZTDS-PPPUBMIESA-N 0.000 description 1
- LNQANWISKPDVTK-LIOBNPLQSA-N (3R,4S)-4-(3,4-dichlorophenyl)-3-phenylpiperidine hydrochloride Chemical compound Cl.C1=C(Cl)C(Cl)=CC=C1[C@@H]1[C@H](C=2C=CC=CC=2)CNCC1 LNQANWISKPDVTK-LIOBNPLQSA-N 0.000 description 1
- SXVCBEJTKQNZJT-PPPUBMIESA-N (3R,4S)-4-(3-bromophenyl)-3-phenylpiperidine hydrochloride Chemical compound Cl.BrC1=CC=CC([C@@H]2[C@@H](CNCC2)C=2C=CC=CC=2)=C1 SXVCBEJTKQNZJT-PPPUBMIESA-N 0.000 description 1
- GYQIUXXCCCGHFP-PPPUBMIESA-N (3R,4S)-4-(4-chlorophenyl)-3-phenylpiperidine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1[C@@H]1[C@H](C=2C=CC=CC=2)CNCC1 GYQIUXXCCCGHFP-PPPUBMIESA-N 0.000 description 1
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- WOTUBBRTDCTGIL-GOTSBHOMSA-N 1-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]ethanone Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)C(C)=O)C2=CC=CC=C2)C=C(C=1)C(F)(F)F)(F)F WOTUBBRTDCTGIL-GOTSBHOMSA-N 0.000 description 1
- HNZJIWIXRPBFAN-UHFFFAOYSA-N 1-cyclopropylpiperazine Chemical compound C1CC1N1CCNCC1 HNZJIWIXRPBFAN-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HNVIQLPOGUDBSU-UHFFFAOYSA-N 2,6-dimethylmorpholine Chemical compound CC1CNCC(C)O1 HNVIQLPOGUDBSU-UHFFFAOYSA-N 0.000 description 1
- QHAABDQQDJXYED-UIOOFZCWSA-N 2-[4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-1-morpholin-4-ylethanone Chemical compound FC(C=1C=C(C(=O)N2C[C@H]([C@H](CC2)N2CCN(CC2)CC(=O)N2CCOCC2)C2=CC=CC=C2)C=C(C1)C(F)(F)F)(F)F QHAABDQQDJXYED-UIOOFZCWSA-N 0.000 description 1
- BBVQDWDBTWSGHQ-UHFFFAOYSA-N 2-chloro-1,3-benzoxazole Chemical compound C1=CC=C2OC(Cl)=NC2=C1 BBVQDWDBTWSGHQ-UHFFFAOYSA-N 0.000 description 1
- YMQRPXBBBOXHNZ-UHFFFAOYSA-N 2-chloro-1-morpholin-4-ylethanone Chemical compound ClCC(=O)N1CCOCC1 YMQRPXBBBOXHNZ-UHFFFAOYSA-N 0.000 description 1
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
- FPQQSNUTBWFFLB-UHFFFAOYSA-N 2-chloro-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CCl FPQQSNUTBWFFLB-UHFFFAOYSA-N 0.000 description 1
- SVDDJQGVOFZBNX-UHFFFAOYSA-N 2-chloroethyl carbonochloridate Chemical compound ClCCOC(Cl)=O SVDDJQGVOFZBNX-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- BGAKSLBTFLVNAH-UHFFFAOYSA-N 3-fluoro-5-(trifluoromethyl)benzoyl chloride Chemical compound FC1=CC(C(Cl)=O)=CC(C(F)(F)F)=C1 BGAKSLBTFLVNAH-UHFFFAOYSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- WXLCQJSOOKWNOZ-DQEYMECFSA-N C(C)N(C(=O)N1CCN(CC1)[C@@H]1[C@@H](CN(CC1)C(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)=O)C1=CC=CC=C1)CC Chemical compound C(C)N(C(=O)N1CCN(CC1)[C@@H]1[C@@H](CN(CC1)C(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)=O)C1=CC=CC=C1)CC WXLCQJSOOKWNOZ-DQEYMECFSA-N 0.000 description 1
- DYKUTPCJHDGNDW-DQEYMECFSA-N CN(CCOC(=O)N1CCN(CC1)[C@@H]1[C@@H](CN(CC1)C(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)=O)C1=CC=CC=C1)C Chemical compound CN(CCOC(=O)N1CCN(CC1)[C@@H]1[C@@H](CN(CC1)C(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)=O)C1=CC=CC=C1)C DYKUTPCJHDGNDW-DQEYMECFSA-N 0.000 description 1
- OZNRSDSVSQHTBH-UHFFFAOYSA-N CNC(CC1)CN1C(CCN(C1)C(C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)=O)C1C1=CC=CC=C1 Chemical compound CNC(CC1)CN1C(CCN(C1)C(C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)=O)C1C1=CC=CC=C1 OZNRSDSVSQHTBH-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- BLCKXSLUIWUJCX-SVBPBHIXSA-N FC(C=1C=C(C(=O)N2CCN(CC2)[C@@H]2[C@@H](CN(CC2)C(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C2=CC=CC=C2)C=C(C=1)C(F)(F)F)(F)F Chemical compound FC(C=1C=C(C(=O)N2CCN(CC2)[C@@H]2[C@@H](CN(CC2)C(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C2=CC=CC=C2)C=C(C=1)C(F)(F)F)(F)F BLCKXSLUIWUJCX-SVBPBHIXSA-N 0.000 description 1
- MJPMFJBJXYRTCM-PMACEKPBSA-N FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CC(CC1)(F)F)C1=CC=CC=C1)(F)F Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CC(CC1)(F)F)C1=CC=CC=C1)(F)F MJPMFJBJXYRTCM-PMACEKPBSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000600903 Homo sapiens Substance-P receptor Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229940123821 Neurokinin 1 receptor antagonist Drugs 0.000 description 1
- 102000028517 Neuropeptide receptor Human genes 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JJSCUXAFAJEQGB-MRVPVSSYSA-N [(1r)-1-isocyanatoethyl]benzene Chemical compound O=C=N[C@H](C)C1=CC=CC=C1 JJSCUXAFAJEQGB-MRVPVSSYSA-N 0.000 description 1
- AMUSSWISJCNOBJ-WDYNHAJCSA-N [(3R,4S)-4-(3-anilinophenyl)-3-phenylpiperidin-1-yl]-[3,5-bis(trifluoromethyl)phenyl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=CC=C1)NC1=CC=CC=C1)C1=CC=CC=C1)(F)F AMUSSWISJCNOBJ-WDYNHAJCSA-N 0.000 description 1
- HKGOZSRUUFFJIC-AHWVRZQESA-N [(3R,4S)-4-[4-(1,3-benzoxazol-2-yl)piperazin-1-yl]-3-phenylpiperidin-1-yl]-[3,5-bis(trifluoromethyl)phenyl]methanone Chemical compound O1C(=NC2=C1C=CC=C2)N2CCN(CC2)[C@@H]2[C@@H](CN(CC2)C(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C2=CC=CC=C2 HKGOZSRUUFFJIC-AHWVRZQESA-N 0.000 description 1
- WTGFYNRENBVWRP-PKTZIBPZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3,4-diphenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=CC=C1)C1=CC=CC=C1)(F)F WTGFYNRENBVWRP-PKTZIBPZSA-N 0.000 description 1
- GIOZLMDIHHBFBL-UNMCSNQZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(2-chlorophenyl)-4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C)C1=C(C=CC=C1)Cl)(F)F GIOZLMDIHHBFBL-UNMCSNQZSA-N 0.000 description 1
- BAEXDRKZOPXLQL-FPOVZHCZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(2-chlorophenyl)-4-morpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=C(C=CC=C1)Cl)(F)F BAEXDRKZOPXLQL-FPOVZHCZSA-N 0.000 description 1
- OPIMMWXRNCVQHH-GOTSBHOMSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(2-methylphenyl)-4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound C1CN(C)CCN1[C@@H]1[C@H](C=2C(=CC=CC=2)C)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 OPIMMWXRNCVQHH-GOTSBHOMSA-N 0.000 description 1
- HECTZASEMNMLOB-VXKWHMMOSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(2-methylphenyl)-4-morpholin-4-ylpiperidin-1-yl]methanone Chemical compound CC1=CC=CC=C1[C@H]1[C@@H](N2CCOCC2)CCN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 HECTZASEMNMLOB-VXKWHMMOSA-N 0.000 description 1
- DLIITBQMYVSGBN-RXVVDRJESA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(3,4-dichlorophenyl)-4-morpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=CC(=C(C=C1)Cl)Cl)(F)F DLIITBQMYVSGBN-RXVVDRJESA-N 0.000 description 1
- NHBNMZYBQVOVGZ-RXVVDRJESA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(3,4-dichlorophenyl)-4-thiomorpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCSCC1)C1=CC(=C(C=C1)Cl)Cl)(F)F NHBNMZYBQVOVGZ-RXVVDRJESA-N 0.000 description 1
- PYLKYKMGKBGSGF-PKTZIBPZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(3-chlorophenyl)-4-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=CC=C1)C1=CC(=CC=C1)Cl)(F)F PYLKYKMGKBGSGF-PKTZIBPZSA-N 0.000 description 1
- BOCOKFLZDCZXON-RXVVDRJESA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-chloro-3-fluorophenyl)-4-morpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCOCC1)C1=CC(=C(C=C1)Cl)F)(F)F BOCOKFLZDCZXON-RXVVDRJESA-N 0.000 description 1
- PZYMUKQQLXEPLN-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-chlorophenyl)-4-thiomorpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCSCC1)C1=CC=C(C=C1)Cl)(F)F PZYMUKQQLXEPLN-SFTDATJTSA-N 0.000 description 1
- GXYWBXGPKGPRTK-SFTDATJTSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-fluorophenyl)-4-pyrrolidin-1-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCCC1)C1=CC=C(C=C1)F)(F)F GXYWBXGPKGPRTK-SFTDATJTSA-N 0.000 description 1
- YMILOBFVZFFDRS-VXKWHMMOSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-methylphenyl)-4-thiomorpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCSCC1)C1=CC=C(C=C1)C)(F)F YMILOBFVZFFDRS-VXKWHMMOSA-N 0.000 description 1
- SYYHXOCRLXLPOB-SXOMAYOGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-(4-morpholin-4-ylphenyl)-4-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=CC=C1)C1=CC=C(C=C1)N1CCOCC1)(F)F SYYHXOCRLXLPOB-SXOMAYOGSA-N 0.000 description 1
- JXYKUCPOWIAITB-SXOMAYOGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-[3-(3-methoxypropylamino)phenyl]-4-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=CC=C1)C1=CC(=CC=C1)NCCCOC)(F)F JXYKUCPOWIAITB-SXOMAYOGSA-N 0.000 description 1
- MRSGCJUYYNYPGI-SXOMAYOGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-(3-pyrrolidin-1-ylphenyl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=CC=C1)N1CCCC1)C1=CC=CC=C1)(F)F MRSGCJUYYNYPGI-SXOMAYOGSA-N 0.000 description 1
- PNRDSNNCMRNXSP-DQEYMECFSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-(4-pyridin-2-ylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C1=NC=CC=C1)C1=CC=CC=C1)(F)F PNRDSNNCMRNXSP-DQEYMECFSA-N 0.000 description 1
- XQBSWYBVJWWTJM-ZEQRLZLVSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-(4-pyrimidin-2-ylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CCN(CC1)C1=NC=CC=N1)C1=CC=CC=C1)(F)F XQBSWYBVJWWTJM-ZEQRLZLVSA-N 0.000 description 1
- UBESRENGJMAHNP-SXOMAYOGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-(4-pyrrolidin-1-ylphenyl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=C(C=C1)N1CCCC1)C1=CC=CC=C1)(F)F UBESRENGJMAHNP-SXOMAYOGSA-N 0.000 description 1
- OHMVJOTUEXNLSK-PKTZIBPZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-3-phenyl-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=CC=C1)C(F)(F)F)C1=CC=CC=C1)(F)F OHMVJOTUEXNLSK-PKTZIBPZSA-N 0.000 description 1
- UCYXDQOVNVFGCO-OSZFHHHMSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(2,6-dimethylmorpholin-4-yl)-3-(4-methylphenyl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)N1CC(OC(C1)C)C)C1=CC=C(C=C1)C)(F)F UCYXDQOVNVFGCO-OSZFHHHMSA-N 0.000 description 1
- NCDSQYOEJCJAKZ-RTWAWAEBSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(3,4-dichlorophenyl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=C(C=C1)Cl)Cl)C1=CC=CC=C1)(F)F NCDSQYOEJCJAKZ-RTWAWAEBSA-N 0.000 description 1
- MYMPTAVGTOHLJA-SXOMAYOGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-(3-morpholin-4-ylphenyl)-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=CC=C1)N1CCOCC1)C1=CC=CC=C1)(F)F MYMPTAVGTOHLJA-SXOMAYOGSA-N 0.000 description 1
- DSSZNLILDOWBNQ-NOZRDPDXSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[2-(2-methoxyethylamino)phenyl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=C(C=CC=C1)NCCOC)C1=CC=CC=C1)(F)F DSSZNLILDOWBNQ-NOZRDPDXSA-N 0.000 description 1
- FJHNNKPZOQEFOG-RSXGOPAZSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[2-[2-(dimethylamino)ethylamino]phenyl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=C(C=CC=C1)NCCN(C)C)C1=CC=CC=C1)(F)F FJHNNKPZOQEFOG-RSXGOPAZSA-N 0.000 description 1
- XHHBHVXMGKAAOD-FTJBHMTQSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[3-(2-methoxyethylamino)phenyl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=CC=C1)NCCOC)C1=CC=CC=C1)(F)F XHHBHVXMGKAAOD-FTJBHMTQSA-N 0.000 description 1
- MXJLRSRYMVWJGS-IZLXSDGUSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[3-(4-methylpiperazin-1-yl)phenyl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=CC=C1)N1CCN(CC1)C)C1=CC=CC=C1)(F)F MXJLRSRYMVWJGS-IZLXSDGUSA-N 0.000 description 1
- LWRRVAWOEOLXGB-SXOMAYOGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[3-(cyclopropylmethylamino)phenyl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=CC=C1)NCC1CC1)C1=CC=CC=C1)(F)F LWRRVAWOEOLXGB-SXOMAYOGSA-N 0.000 description 1
- IJJUDUAJBDJYSQ-SXOMAYOGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-[3-(diethylamino)phenyl]-3-phenylpiperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC(=CC=C1)N(CC)CC)C1=CC=CC=C1)(F)F IJJUDUAJBDJYSQ-SXOMAYOGSA-N 0.000 description 1
- AVDWFECENBVMFG-SXOMAYOGSA-N [3,5-bis(trifluoromethyl)phenyl]-[(3R,4S)-4-phenyl-3-(3-pyrrolidin-1-ylphenyl)piperidin-1-yl]methanone Chemical compound FC(C=1C=C(C=C(C=1)C(F)(F)F)C(=O)N1C[C@H]([C@H](CC1)C1=CC=CC=C1)C1=CC(=CC=C1)N1CCCC1)(F)F AVDWFECENBVMFG-SXOMAYOGSA-N 0.000 description 1
- SRVWSSOUVOLBMQ-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-chlorophenyl)-4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCN(CC2)C2CC2)C=2C=CC(Cl)=CC=2)=C1 SRVWSSOUVOLBMQ-UHFFFAOYSA-N 0.000 description 1
- CCXDRJAINCWDAQ-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-chlorophenyl)-4-morpholin-4-ylpiperidin-1-yl]methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCOCC2)C=2C=CC(Cl)=CC=2)=C1 CCXDRJAINCWDAQ-UHFFFAOYSA-N 0.000 description 1
- YROSDGAJJFMAGJ-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-fluorophenyl)-4-[3-(methylamino)pyrrolidin-1-yl]piperidin-1-yl]methanone Chemical compound C1C(NC)CCN1C1C(C=2C=CC(F)=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 YROSDGAJJFMAGJ-UHFFFAOYSA-N 0.000 description 1
- TUIDWNHLUFCRLS-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-methylphenyl)-4-(4-methylsulfonylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1C1C(N2CCN(CC2)S(C)(=O)=O)CCN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 TUIDWNHLUFCRLS-UHFFFAOYSA-N 0.000 description 1
- JSDRETCBRAMLMU-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[3-(4-methylphenyl)-4-(4-phenylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1C1C(N2CCN(CC2)C=2C=CC=CC=2)CCN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 JSDRETCBRAMLMU-UHFFFAOYSA-N 0.000 description 1
- SVAYRKLDOZPACO-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]-[4-(4-methylpiperazin-1-yl)-3-phenylpiperidin-1-yl]methanone Chemical compound C1CN(C)CCN1C1C(C=2C=CC=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 SVAYRKLDOZPACO-UHFFFAOYSA-N 0.000 description 1
- CMKVWLDLYUIJPK-SVBPBHIXSA-N [4-[(3R,4S)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazin-1-yl]-phenylmethanone Chemical compound C(C1=CC=CC=C1)(=O)N1CCN(CC1)[C@@H]1[C@@H](CN(CC1)C(=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=CC=C1 CMKVWLDLYUIJPK-SVBPBHIXSA-N 0.000 description 1
- JREGZZLYXNTSNK-UHFFFAOYSA-N [4-[1-[3,5-bis(trifluoromethyl)benzoyl]-3-(4-chlorophenyl)piperidin-4-yl]piperazin-1-yl]-cyclopropylmethanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(C(CC2)N2CCN(CC2)C(=O)C2CC2)C=2C=CC(Cl)=CC=2)=C1 JREGZZLYXNTSNK-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- CLUPOLFGIGLMIQ-UHFFFAOYSA-N heptane;propan-2-ol Chemical compound CC(C)O.CCCCCCC CLUPOLFGIGLMIQ-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- PFPSZGPAQFBVHZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-[(4-phenyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound ClC1=CC=CC(NC(=O)CSC=2N(C(C=3C=CN=CC=3)=NN=2)C=2C=CC=CC=2)=C1 PFPSZGPAQFBVHZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- GBDKKPDLEMYCMB-ZEQRLZLVSA-N tert-butyl 4-[(3r,4s)-1-[3,5-bis(trifluoromethyl)benzoyl]-3-phenylpiperidin-4-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1[C@@H]1[C@H](C=2C=CC=CC=2)CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CC1 GBDKKPDLEMYCMB-ZEQRLZLVSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01102557 | 2001-02-06 | ||
EP01102557 | 2001-02-06 | ||
PCT/EP2002/000851 WO2002062784A1 (en) | 2001-02-06 | 2002-01-28 | Piperidinee derivatives as neurokinin 1 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60203481D1 DE60203481D1 (de) | 2005-05-04 |
DE60203481T2 true DE60203481T2 (de) | 2006-02-16 |
Family
ID=8176398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60203481T Expired - Lifetime DE60203481T2 (de) | 2001-02-06 | 2002-01-28 | Piperidinderivate als neurokinin 1 antagonisten |
Country Status (17)
Country | Link |
---|---|
US (1) | US6642226B2 (es) |
EP (1) | EP1360184B1 (es) |
JP (1) | JP4181409B2 (es) |
KR (1) | KR100566470B1 (es) |
CN (1) | CN1229373C (es) |
AR (1) | AR035427A1 (es) |
AT (1) | ATE292128T1 (es) |
AU (1) | AU2002228072B2 (es) |
BR (1) | BR0206915A (es) |
CA (1) | CA2435946C (es) |
DE (1) | DE60203481T2 (es) |
DK (1) | DK1360184T3 (es) |
ES (1) | ES2238560T3 (es) |
MX (1) | MXPA03006991A (es) |
PT (1) | PT1360184E (es) |
WO (1) | WO2002062784A1 (es) |
ZA (1) | ZA200305887B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2696B1 (en) | 2002-12-23 | 2013-03-03 | شركة جانسين فارماسوتيكا ان. في | Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists |
US7514424B2 (en) | 2002-12-23 | 2009-04-07 | Janssen Pharmaceutica N.V. | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists |
JO2485B1 (en) * | 2002-12-23 | 2009-01-20 | شركة جانسين فارماسوتيكا ان. في | 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists |
WO2004056800A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
WO2004110415A2 (en) | 2003-06-10 | 2004-12-23 | Janssen Pharmaceutica N.V. | Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments |
JO2525B1 (en) * | 2004-04-08 | 2010-03-17 | شركة جانسين فارماسوتيكا ان. في | Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin |
WO2006071958A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
CA2598418A1 (en) * | 2005-02-16 | 2006-08-31 | Schering Corporation | Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity |
WO2006089674A2 (en) | 2005-02-25 | 2006-08-31 | F.Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
ATE478075T1 (de) * | 2005-03-08 | 2010-09-15 | Janssen Pharmaceutica Nv | Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten |
ES2342323T3 (es) | 2005-09-16 | 2010-07-05 | Janssen Pharmaceutica N.V. | Ciclopropilaminas como moduladores del receptor h3 de histamina. |
US8067415B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
ES2620818T3 (es) | 2006-12-14 | 2017-06-29 | Janssen Pharmaceutica N.V. | Procedimiento para la preparación de derivados de piperazinil y diazepanil benzamida |
EA200970706A1 (ru) | 2007-01-24 | 2010-02-26 | Глэксо Груп Лимитед | Новые фармацевтические композиции |
US8063075B2 (en) * | 2008-06-10 | 2011-11-22 | Hoffmann-La Roche Inc. | Pyrrolidine ether derivatives as NK3 receptor antagonists |
WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
NO2729147T3 (es) | 2011-07-04 | 2018-02-03 | ||
JP2021514976A (ja) | 2018-02-26 | 2021-06-17 | オスペダーレ・サン・ラッファエーレ・エッセエッレエッレ | 眼痛の治療における使用のためのnk−1拮抗薬 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH545288A (de) | 1966-08-18 | 1974-01-31 | Sandoz Ag | Verfahren zur Herstellung neuer Piperidon-Derivate |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
NZ277839A (en) | 1993-12-29 | 1998-01-26 | Merck Sharp & Dohme | Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
GB9600235D0 (en) | 1996-01-05 | 1996-03-06 | Pfizer Ltd | Therapeutic agents |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
US6291465B1 (en) | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
US6291496B1 (en) | 1999-12-27 | 2001-09-18 | Andrew J. Dannenberg | Treating cancers associated with overexpression of class I family of receptor tyrosine kinases |
-
2002
- 2002-01-25 US US10/057,450 patent/US6642226B2/en not_active Expired - Fee Related
- 2002-01-28 CN CNB028046064A patent/CN1229373C/zh not_active Expired - Fee Related
- 2002-01-28 JP JP2002563137A patent/JP4181409B2/ja not_active Expired - Fee Related
- 2002-01-28 PT PT02710043T patent/PT1360184E/pt unknown
- 2002-01-28 DK DK02710043T patent/DK1360184T3/da active
- 2002-01-28 EP EP02710043A patent/EP1360184B1/en not_active Expired - Lifetime
- 2002-01-28 KR KR1020037010336A patent/KR100566470B1/ko not_active IP Right Cessation
- 2002-01-28 AT AT02710043T patent/ATE292128T1/de not_active IP Right Cessation
- 2002-01-28 MX MXPA03006991A patent/MXPA03006991A/es active IP Right Grant
- 2002-01-28 BR BR0206915-6A patent/BR0206915A/pt not_active IP Right Cessation
- 2002-01-28 CA CA002435946A patent/CA2435946C/en not_active Expired - Fee Related
- 2002-01-28 ES ES02710043T patent/ES2238560T3/es not_active Expired - Lifetime
- 2002-01-28 DE DE60203481T patent/DE60203481T2/de not_active Expired - Lifetime
- 2002-01-28 WO PCT/EP2002/000851 patent/WO2002062784A1/en active IP Right Grant
- 2002-01-28 AU AU2002228072A patent/AU2002228072B2/en not_active Ceased
- 2002-02-01 AR ARP020100349A patent/AR035427A1/es unknown
-
2003
- 2003-07-30 ZA ZA2003/05887A patent/ZA200305887B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA03006991A (es) | 2003-11-18 |
KR100566470B1 (ko) | 2006-03-31 |
CN1229373C (zh) | 2005-11-30 |
ES2238560T3 (es) | 2005-09-01 |
JP4181409B2 (ja) | 2008-11-12 |
CA2435946A1 (en) | 2002-08-15 |
EP1360184A1 (en) | 2003-11-12 |
AR035427A1 (es) | 2004-05-26 |
BR0206915A (pt) | 2004-02-03 |
US20020151547A1 (en) | 2002-10-17 |
WO2002062784A8 (en) | 2002-10-03 |
PT1360184E (pt) | 2005-06-30 |
JP2004525892A (ja) | 2004-08-26 |
KR20030070619A (ko) | 2003-08-30 |
CN1491222A (zh) | 2004-04-21 |
US6642226B2 (en) | 2003-11-04 |
WO2002062784A1 (en) | 2002-08-15 |
DE60203481D1 (de) | 2005-05-04 |
ATE292128T1 (de) | 2005-04-15 |
DK1360184T3 (da) | 2005-08-01 |
EP1360184B1 (en) | 2005-03-30 |
CA2435946C (en) | 2008-10-07 |
AU2002228072B2 (en) | 2006-08-03 |
ZA200305887B (en) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60203481T2 (de) | Piperidinderivate als neurokinin 1 antagonisten | |
DE60106287T2 (de) | Chemische verbindungen | |
US6521621B1 (en) | 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives | |
DE69628035T2 (de) | In 4-stellung substituierte piperidin-analoge und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten | |
EP0855999B1 (en) | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives as tachykinin receptor antagonists | |
DE602004006431T2 (de) | Derivate von n-äheteroaryl(piperidin-2-yl)methylübenzamid, verfahren zu deren herstellung und deren anwendung in therapeutika | |
DE602005004404T2 (de) | Als histamin-3-rezeptorliganden einsetzbare naphthalene-derivate | |
DE60123420T2 (de) | Cyclohexylderivate und ihre anwendung als therapeutische mittel | |
DE60318583T2 (de) | N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung | |
DE69213276T2 (de) | Substituierte Piperidimylmethyl-Ester von 3-Indolcarbonsäure | |
DE60302137T2 (de) | Piperidinderivate | |
AU2002228072A1 (en) | Piperidinee derivatives as neurokinin 1 antagonists | |
DE60213629T2 (de) | Piperidinverbindungen als muscarinantagonisten | |
DE69721742T2 (de) | N-substituierte 4-((4'-aminobenzoyl)-oxymethyl)-piperidine mit gastrokinetischen eigenschaften | |
DE60206781T2 (de) | 2-substituierte 1-arylpiperazine als tachykinin-antagonisten und/oder serotonin-wiederaufnahme-hemmer | |
DE69725457T2 (de) | Piperazinderivate als neurokinin-antagonisten | |
DE60216627T2 (de) | Neue substituierte 4-phenyl-4-ä1h-imidazo-2-ylü-piperidin-derivate und ihre anwendung als selective delta-opioid-agonisten | |
DE60112725T2 (de) | Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors | |
AT395850B (de) | Verfahren zur herstellung von neuen psychogeriatrischen diazinylpiperidinderivaten von cyclischen amiden und imiden sowie von deren saeureadditionssalzen | |
DE3785393T2 (de) | 4-(aroylamino)piperidinbutanamide derivate. | |
DE69119282T2 (de) | Aminobenzolverbindungen, Herstellung und Verwendung | |
DE60307308T2 (de) | 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel | |
DE69925160T2 (de) | Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität | |
DE69024385T2 (de) | Verbindung zur Behandlung von Störungen des Neurotransmittersystems im Gehirn | |
DE10051321A1 (de) | Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |